Background
AMPLIFY was a phase III randomized open-label trial evaluating fixed-duration acalabrutinib + venetoclax + obinutuzumab (AVO) and acalabrutinib + venetoclax (AV) versus investigator's choice chemoimmunotherapy (CIT: FCR or BR) as first-line treatment for CLL. The trial tested whether combining a selective BTK inhibitor with a BCL-2 inhibitor as a fixed-duration doublet or triplet could achieve high MRD-negativity rates while offering a finite treatment approach superior to CIT, including in high-risk IGHV-unmutated and del17p CLL. Patients with del17p/TP53 mutation were excluded from the primary efficacy analysis population per design.
Interventions and follow up
Arm A: Investigator's choice chemoimmunotherapy: FCR (fludarabine + cyclophosphamide + rituximab) × 6 or BR (bendamustine + rituximab) × 6 cycles
Arm B: Acalabrutinib 100 mg BID × 14 cycles + venetoclax (5-week ramp-up to 400 mg daily, cycles 3–14) [AV]
Arm C: Acalabrutinib + venetoclax + obinutuzumab (1000 mg cycles 2–7) [AVO]
Primary endpoint: PFS per IRC (IWCLL 2018) (AV vs CIT, AVO vs CIT)
mFollow up: 40.8 months
Arm B: Acalabrutinib 100 mg BID × 14 cycles + venetoclax (5-week ramp-up to 400 mg daily, cycles 3–14) [AV]
Arm C: Acalabrutinib + venetoclax + obinutuzumab (1000 mg cycles 2–7) [AVO]
Primary endpoint: PFS per IRC (IWCLL 2018) (AV vs CIT, AVO vs CIT)
mFollow up: 40.8 months
Results
3-yr PFS (AVO vs CIT): 83.1% vs 63.5% (HR 0.42, 95% CI 0.31–0.57, P<.001)
3-yr PFS (AV vs CIT): 76.5% vs 63.5% (HR 0.65, 95% CI 0.49–0.87, P=.003)
uMRD (peripheral blood 10⁻⁴, end of treatment): AVO 72% vs CIT 39%; AV 60% vs CIT 39%
3-yr OS: AVO 94.3%, AV 94.3%, CIT 90.7% (immature)
del17p/TP53-mutant 3-yr PFS: AVO 72.7% vs CIT 36.3%
3-yr PFS (AV vs CIT): 76.5% vs 63.5% (HR 0.65, 95% CI 0.49–0.87, P=.003)
uMRD (peripheral blood 10⁻⁴, end of treatment): AVO 72% vs CIT 39%; AV 60% vs CIT 39%
3-yr OS: AVO 94.3%, AV 94.3%, CIT 90.7% (immature)
del17p/TP53-mutant 3-yr PFS: AVO 72.7% vs CIT 36.3%
Adverse events
Overall: Grade ≥3 AEs AVO 72.1%, AV 62.8%, CIT 62.7%
Hematologic: Grade ≥3 neutropenia AVO 38%, AV 26%, CIT 50%
Cardiac: Atrial fibrillation (all grades) AVO 3.8%, AV 3.1%, CIT 1.1%; Grade ≥3 TLS AVO 1.0%, AV 0.7% (venetoclax ramp-up)
Infections: Grade ≥3 infections AVO 19%, AV 14%, CIT 19%
Other: Richter's transformation ~2% across arms; second primary malignancies comparable across arms
Hematologic: Grade ≥3 neutropenia AVO 38%, AV 26%, CIT 50%
Cardiac: Atrial fibrillation (all grades) AVO 3.8%, AV 3.1%, CIT 1.1%; Grade ≥3 TLS AVO 1.0%, AV 0.7% (venetoclax ramp-up)
Infections: Grade ≥3 infections AVO 19%, AV 14%, CIT 19%
Other: Richter's transformation ~2% across arms; second primary malignancies comparable across arms
Conclusions
Fixed-duration AVO and AV significantly prolonged PFS compared to chemoimmunotherapy in treatment-naive CLL, with markedly higher uMRD rates and particular benefit in high-risk subgroups (del17p, IGHV-unmutated), establishing finite BTKi + BCL-2 inhibitor combinations as a new standard that may replace both CIT and continuous BTKi monotherapy in frontline CLL.
Key Limitations
CIT comparator (FCR/BR) is now considered suboptimal and was not directly compared to CLL14 VO, ELEVATE-TN AO, or continuous BTKi; AVO vs AV was not a pre-specified primary comparison; OS data immature; venetoclax ramp-up requires TLS risk management; optimal choice between AVO (higher uMRD, more toxicity) and AV (doublet) is undefined; head-to-head comparison to VO is needed; cost/complexity of the triplet is relevant for access; re-treatment strategy after fixed-duration AVO relapse is not established.
Clinical Context
AMPLIFY (NEJM 2025) represents the convergence of BTKi and BCL-2 inhibitor strategies into fixed-duration combination therapy, synthesizing ELEVATE-TN (acalabrutinib activity) and CLL14 (fixed-duration venetoclax) paradigms. The 83% 3-year PFS for AVO and high uMRD rates in del17p position the combination as potentially practice-changing for high-risk CLL where CIT has historically failed. The questions of continuous BTKi vs fixed-duration combination, optimal sequencing at relapse, and a future head-to-head with CLL14 VO will define the next chapter of frontline CLL. Regulatory review and ELN/iwCLL guideline incorporation of AVO/AV are anticipated.
References